CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Wholly owned lead asset, Seladelpar, is a potent, selective, orally active PPARδ agonist currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof of concept in PBC. Additionally, CymaBay has out-licensed US rights to Arhalofenate to Kowa Pharmaceuticals America, Inc. Arhalofenate is a potential urate-lowering anti-flare therapy that has been found to reduce painful flares in joints while at the same time lowering serum uric acid by promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. CymaBay retains full development and commercialization rights for arhalofenate outside the U.S.
Employees: 51-200
Total raised: $100M
Founded date: 1988
Investors 6
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| - | Omega Fund... | omegafunds... |
| 23.03.2023 | Avoro Capi... | avorocapit... |
| 03.08.2021 | Abingworth... | abingworth... |
| - | VantagePoi... | vpcp.com |
| - | Bay City C... | baycitycap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.08.2021 | - | $100M | Abingworth... |
Mentions in press and media 10
| Date | Title | Description | Source |
| 25.03.2024 | Gilead Sciences Completes Acquisition of CymaBay, for Approx... | Gilead Sciences (Nasdaq: GILD), a Foster City, CA-based biopharmaceutical company, acquired CymaBay ... | finsmes.co... |
| 08.03.2024 | Seladelpar (MBX-8025) Market Overview and Outlook 2024-2032:... | - | globenewsw... |
| 06.02.2023 | CymaBay Therapeutics to Present at the SVB Securities Global... | /EIN News/ -- NEWARK, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: ... | einpresswi... |
| 03.11.2022 | CymaBay Therapeutics to Present at Upcoming Investment Confe... | /EIN News/ -- NEWARK, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: ... | einpresswi... |
| 11.11.2021 | CymaBay Reports Third Quarter and Nine Months Ended Septembe... | Over 100 clinical sites now activated in RESPONSE Phase 3 registration study of seladelpar for patie... | marketscre... |
| 12.08.2021 | CymaBay Therapeutics : Reports Second Quarter and Six Months... | Secured up to $100 million of additional development funding through a non-dilutive financing transa... | marketscre... |
| 02.08.2021 | CymaBay secures $100M to bankroll phase 3 development of res... | A little over a year after resurrecting the liver disease drug seladelpar, CymaBay Therapeutics now ... | fiercebiot... |
| 02.08.2021 | CymaBay Announces $100 Million Non-Dilutive Financing with A... | - | abingworth... |
| 02.08.2021 | CymaBay Therapeutics : Announces $100 Million Non-Dilutive F... | Risk-sharing agreement with Abingworth will fund seladelpar Phase 3 development program for PBC Cyma... | marketscre... |
| 02.08.2021 | CymaBay secures $100M to bankroll phase 3 development of res... | A little over a year after resurrecting the liver disease drug seladelpar, CymaBay Therapeutics now ... | fiercebiot... |